ADOCIA News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

12.02.18	Number of Shares and Voting Rights of ADOCIA as of January 31, 2018 (Businesswire)
12.02.18	Adocia: Additional Resources Allocated to the Liquidity Agreement (Businesswire)
09.02.18	Adocia to Present at the 2018 BIO CEO & Investor Conference in New York (Businesswire)
06.02.18	Adocia Files Additional Arbitration Claims Against Eli Lilly & Company (Businesswire)
25.01.18	Adocia Announces Positive Topline Data From a Dose-Proportionality Study of BioChaperone® Combo in People with Type 2 Diabetes (Businesswire)
10.01.18	Number of Shares and Voting Rights of ADOCIA as of December 31, 2017 (Businesswire)
09.01.18	Half Year Report on Adocia’s Liquidity Agreement with Kepler Capital Markets (Businesswire)
08.01.18	Adocia Announces Its Financial Calendar for 2018 (Businesswire)
04.01.18	Adocia Announces Expanded BioChaperone® Product Portfolio beyond Diabetes (Businesswire)
07.12.17	Number of Shares and Voting Rights of ADOCIA as of November 30, 2017 (Businesswire)
06.12.17	Adocia Announces Positive Topline Study Results Comparing Ultra-Rapid Insulin BioChaperone® Lispro with Novolog® and Fiasp® in People with Type 1 Diabetes (Businesswire)
20.11.17	Adocia Reports Topline Results of BioChaperone® Glucagon Phase 1 Study (Businesswire)
08.11.17	Number of Shares and Voting Rights of ADOCIA as of October 31, 2017 (Businesswire)
12.10.17	Number of Shares and Voting Rights of ADOCIA as of September 30, 2017 (Businesswire)
11.10.17	Adocia Announces Financial Results for the Third Quarter 2017 (Businesswire)
18.09.17	Number of Shares and Voting Rights of ADOCIA as of August 31, 2017 (Businesswire)
05.09.17	Adocia Announces Two Data Presentations at the 53rd Annual Meeting of the European Association for the Study of Diabetes (Businesswire)
26.07.17	Adocia Announces Appointment of Dr. Stanislav Glezer as Chief Medical Officer (Businesswire)
19.07.17	Adocia Presents First Half 2017 Financial Results (Businesswire)
30.05.17	Adocia Announces Six Data Presentations at the American Diabetes Association® 77th Scientific Sessions (Businesswire)
04.01.17	Adocia Announces Its Financial Calendar for 2017 (Businesswire)
10.11.16	Adocia to Participate in Upcoming Investor Conferences (Businesswire)
07.11.16	Adocia Receives the 1st Prize for ‘Profitable Growth’ and the 3rd ‘Technology Fast 50’ Prize as Part of The 2016 Deloitte In Extenso Technology Fast 50 Grand Rhône Alpes (Businesswire)
27.10.16	Adocia Announces Positive Topline Results from a Phase 1b Clinical Trial Measuring the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100 (Businesswire)
12.10.16	Adocia Announces Third Quarter 2016 Financial Results (Businesswire)
22.09.16	Adocia Received the EY Global Company Award for the Auvergne Rhône-Alpes Region (Businesswire)
20.09.16	Adocia Launches a New Clinical Study of BioChaperone® Combo, Its Combination of Long-Acting Insulin Glargine and Fast-Acting Insulin Lispro, in People with Type 2 Diabetes (Businesswire)
19.09.16	Adocia to Hold Conference Call for Investors to Provide Business Update and Growth Perspectives (Businesswire)
08.09.16	Adocia to Present Clinical Data Validating BioChaperone® Technology at the 2016 EASD Annual Meeting (Businesswire)
07.09.16	Adocia Announces new BioChaperone Program Combining a Basal Insulin and GLP-1s (Businesswire)
21.07.16	Adocia Today Announces the Release of Its Interim Financial Report as of June 30, 2016 (Businesswire)
20.07.16	Adocia Presents First Half 2016 Financial Results (Businesswire)
05.07.16	Half Year Report on Adocia’s Liquidity Agreement with Kepler Capital Markets (Businesswire)
08.06.16	Adocia Reinforces Its Focus on Diabetes with the Launch of a New Project: BioChaperone Glucagon (Businesswire)
06.06.16	Adocia to Present Data Validating the Potential of BioChaperone® Technology at the American Diabetes Association® 76Th Scientific Sessions (Businesswire)
02.06.16	Adocia to Present at the Jefferies 2016 Global Healthcare Conference (Businesswire)
31.05.16	Adocia and Lilly Announce Positive Topline Results from a Phase 1 Study Evaluating Ultra-Rapid Insulin BioChaperone Lispro U100 in Healthy Japanese Subjects (Businesswire)
13.05.16	Adocia to Hold Its Annual Shareholders’ Meeting on June 21, 2016 in Paris (Businesswire)
03.05.16	Adocia strengthens its BioChaperone Combo patent portfolio (Businesswire)
27.04.16	Adocia and Lilly Announce Positive Topline Results from a Phase 1b Study of Repeated Administration of Ultra-Rapid BioChaperone Lispro U100 in People with Type 2 Diabetes (Businesswire)
14.04.16	Adocia Announces First Quarter 2016 Results (Businesswire)
11.04.16	Adocia Initiates a Phase 1/2 Clinical Trial on the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100 (Businesswire)
25.03.16	ADOCIA Confirms Its Eligibility for the PEA - PME (Businesswire)
21.03.16	Adocia Welcomes Internationally Renowned Diabetes Experts to Inaugural Medical Advisory Board (Businesswire)
16.03.16	ADOCIA Announced Its Financial Results for 2015 (Businesswire)
14.03.16	Adocia and Lilly Announce Positive Topline Results from a Phase 1b Study of Repeated Administration of Ultra-Rapid BioChaperone Lispro in Patients with Type 1 Diabetes (Businesswire)
16.02.16	Adocia Announced Significant Revenue Growth With EUR 36.9 Million (EUR 0.7 Million in 2014) in Revenue and a Solid Cash Position Of EUR 72 Million as of December 31, 2015 (Businesswire)
04.02.16	Adocia to Present at the 2016 Leerink Global Healthcare Conference (Businesswire)
29.01.16	Adocia and Lilly Initiate Phase 1b Study Evaluating Ultra-Rapid Insulin BioChaperone Lispro U100 in Healthy Japanese Subjects (Businesswire)
08.01.16	Half year report on Adocia’s liquidity agreement with Kepler Capital Markets (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu ADOCIA

Aktien Top/Flop

Meistgelesene Nachrichten